Heart Transplantation in Pediatric Patients: Twelve-Year Experience of the Asan Medical Center by Shin, Hong Ju et al.
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Heart Transplantation in Pediatric Patients: Twelve-Year 
Experience of the Asan Medical Center
Heart transplantation is a standard treatment for end-stage heart disease. Pediatric heart 
transplantation, however, is not frequently performed due to the shortage of pediatric 
heart donors. This is the first report of pediatric heart transplantation in Korea. Our 
retrospective study included 37 patients younger than 18 yr of age who underwent heart 
transplantation at Asan Medical Center between August 1997 and April 2009. Preoperative 
diagnosis was either cardiomyopathy (n = 29, 78.3%) or congenital heart disease (n = 8, 
22.7%). Mean follow up period was 56.9 ± 44.6 months. There were no early death, but 
7 late deaths (7/37, 18.9%) due to rejection after 11, 15, 41 months (n = 3), infection 
after 5, 8, 10 months (n = 3), suspicious ventricular arrhythmia after 50 months (n = 1). 
There was no significant risk factor for survival. There were 25 rejections (25/37, 67.6%); 
less than grade II occurred in 17 patients (17/25, 68%) and more than grade II occurred in 
8 patients (8/25, 32%). Actuarial 1, 5, and 10 yr survival was 88.6%, 76.8%, and 76.8%. 
Our midterm survival of pediatric heart transplantation showed excellent results. We hope 
this result could be an encouraging message to do more pediatric heart transplantation in 
Korean society.
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ORIGINAL ARTICLE
Cell Therapy & Organ Transplantation
INTRODUCTION
Heart transplantation is a standard surgical treatment for end-
stage heart disease in both adults and children. Pediatric heart 
transplantation, however, is not frequently performed due to 
the shortage of pediatric heart donors. The total number of pe-
diatric heart transplant procedures has remained stable for the 
past 15 yr at approximately 400 procedures per year and the to-
tal number of transplant centers reporting data has stabilized at 
approximately 80 (1). The first adult heart transplantation in 
Korea was performed in November, 1992 (2) and long-term re-
sults of 112 heart transplantation in a single center was reported 
lately (3). However, there is no report of pediatric heart trans-
plantation until now. So we first report 12-yr experience of pe-
diatric heart transplantation in Korea. 
MATERIALS AND METHODS
Patients and surgical techniques
All patients younger than 18 yr of age who underwent heart 
transplantation at Asan Medical Center between August 1997 
and April 2009 were included in this retrospective study: a total 
of 37 transplantations were reviewed for early and long-term 
outcomes. 
  Preoperative diagnosis was either cardiomyopathy (n = 29, 
78.3%) or congenital heart disease (n = 8, 21.7%). The most com-
mon diagnosis was dilated cardiomyopathy (DCMP) (n = 23, 
62.2%). The median recipient age was 12.5 yr (range, 3 months 
to 17 yr). There were 4 children less than 5 yr, including 1 child 
less than 1 yr (Fig. 1). The male patients were 23 (62.2%) and the 
median recipient body weight was 38.7 kg (range, 3.6 to 67 kg). 
The median donor age was 17 yr (range, 2 to 48 yr) (Fig. 2), and 
the male donor patients were 23 (62.2%) and the median donor 
body weight was 43.5 kg (range, 14 to 73 kg) (Table 1). Sex mis-
match was present in 14 cases. Male to female donor-recipient 
matching occurred in 7 cases whereas female to male donor-re-
cipient matching occurred in 7 cases. The median time interval 
between registration and operation was 156 days (range, 0 to 
877 days). Donor and recipient body weight ratio was 1.59 ± 0.9 
(range, 0.67 to 4.42). The number of patients with donor and re-
cipient body weight ratio greater than 2.5 were 3. There were no 
patients with renal insufficiency or hepatic failure. Surgery was 
all performed in bicaval technique and 8 patients with congeni-
tal heart disease (CHD) had surgical interventions before heart 
transplantation (Table 2).Shin HJ, et al.  •  Heart Transplantation in Pediatric Patients: AMC Experience 
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Immunosuppression protocol
From August 1997 to June 1999, the preoperative immunosup-
pressive protocol comprised induction with cyclosporine (No-
vartis Pharma Stein AG, Stein, Switzerland) 3-5 mg/kg and aza-
thioprine (GlaxoSmithKline, Brentford, UK) 2-3 mg/kg per os 
(PO).
  After June 1999, the preoperative immunosuppressive proto-
col comprised daclizumab (Roche, Basel, Switzerland) (anti-IL2 
receptor monoclonal antibody) 1mg/kg mixed with normal sa-
line 50 Ml intravenously (IV), replacement of azathioprine with 
mycophenolate mofetil (Roche, Basel, Switzerland) 500 mg PO 
and administration of cyclosporin 2-3 mg/kg PO. Intraopera-
tively, methylprednisolone (Pfizer Inc., NY, NY) 5-10 mg/kg IV 
was injected after aortic declamping simultaneously. Postoper-
atively, mycophenolate mofetil 500 mg b.i.d. PO and daclizum-
ab were administered as scheduled to maintain the WBC count 
at 4,000-6,000/μL. Postoperatively, cyclosporine trough level was 
maintained at 300-400 ng/dL by the EMI method during the 
first year and 150-200 ng/mL thereafter. Methylprednisolone 
(Kunwha Pharmaceutical Co, Seoul, Korea) was initially given 
at 1 mg/kg/day and then was decreased to 0.25 mg/kg/day at       
1 month and 0.1 mg/kg/day at 1 yr. For preventing chronic re-
jection, pravastain (CJ Pharma, Seoul, Korea) 5 mg PO was start-
ed and then 10 mg PO was maintained. To evaluate rejection, 
endomyocardial biopsy, echocardiography, EKG, and chest ra-
dopgraph were performed at postoperatively 2 weeks, 4 weeks, 
2 months, 3 months, 6 months, 12 months and then every 6 
months. In case of rejection, methylprednisolone 10 mg/kg IV 
pulse therapy for 3 days was started and then methylpredniso-
lone 1 mg/kg PO was started and then tapered as usual amount.
Table 1. Patients’ characteristics
No. of patients   37
Recipient
   M:F
   Age (yr)
   Body weight (kg)
 
23:14
11.4 ± 4.6
  37.6 ± 17.7
Donor
   M:F
   Age (yr)
   Body weight (kg)
 
23:14
  19.8 ± 12.2
  43.8 ± 15.6
Diagnosis
   Cardiomyopathy
   DCMP
   RCMP
   HCMP
   ICMP
   Congenital heart disease
   RV or LV dysfunction after TOF total correction
   LV dysfunction with mitral valve disease
   Fontan failure
 
29 (78.3%)
23
  2
  2
  2
  8 (21.7%)
  2
  2
  4
M, male; F, female; DCMP, dilated cardiomyopathy; RCMP, restrictive cardiomyopathy; 
HCMP, hypertrophic cardiomyopathy; ICMP, ischemic cardiomyopathy; RV, right ven­
tricle; TOF, tetralogy of Fallot; LV, left ventricle.
Table 2. Representative previous surgeries of pediatric patients with congenital heart 
disease
Patient No. Age at  
transplant (yr) Diagnosis Previous procedures
1 13.8 TOF Total correction
2   3.4 TA Ic 1) PAB 2) BCS
3 10.0 DORV with 
remote  
VSD, PA
1) RMBT
2) Pulmonary valvotomy RMBT 
ligation
3) LMBT
4) Fontan  Bilateral BCS Atrial 
septectomy
4   7.6 Congenital MR MVR
5 12.4 TGA with  
VSD, PS
1) RMBT
2) BCS
3) Fontan 
 PPM implantation
6 0.3 LVOTO, MR 1) LVOTO relieve MVP
2) Ross operation
3) MVR
7 11 TA IIb 1) RMBT
2) Fontan 
8 15.6 TOF Total correction
TOF, tetralogy of Fallot; TA, tricuspid atresia; PAB, pulmonary artery banding; BCS, 
bidirectional cavopulmonary shunt; DORV, double outlet right ventricle; PA, pulmonary 
atresia; RMBT, right modified Blalock­Taussig shunt; LMBT, left modified Blalock­Taussig 
shunt; PPM, permanent pacemaker; LVOTO, left ventricular outflow tract obstruction; 
MR, mitral regurgitation; MVR, mitral valve replacement; TGA, transposition of the 
great arteries; VSD, ventricular septal defects; PS, pulmonary stenosis; MVP, mitral 
valvuloplasty.
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Fig. 1. Recipient age distribution.
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Fig. 2. Donor age distribution.
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Infection prophylaxis
As previously reported (3), preoperatively, hepatitis B virus vac-
cination was carried out if HBsAg was (-) and HBsAb was (-). 
Pneumococcal vaccination was also routinely done along with 
postoperative sulfamethoxazole and trimethoprim (Roche, Ba-
sel, Switzerland) administration throughout the first year if tol-
erable. Cytomegalovirus (CMV) prophylaxis with ganciclovir 
(Roche, Basel, Switzerland) IV was carried out for 4 weeks if the 
recipient CMV was IgG (+). If the recipient CMV was IgG (-) but 
the donor CMV was IgG (+), IV ganciclovir was given for 4 weeks 
and then switched to oral ganciclovir for another 2-3 months.
Follow-up
Routine follow-up examination for detection of acute or chron-
ic rejection, endomyocardial biopsy, echocardiography, EKG, 
and chest radiopgraph were performed according to the sched-
ule as mentioned above. Evaluation of graft vascular disease 
(GVD) was performed by coronary angiogram and intravascu-
lar ultrasonography at postoperatively 2 weeks, and 12 months. 
Hypertension and hypercholesteremia were treated with angio-
tensin converting enzyme (ACE) inhibitors, calcium antagonists, 
and HMG CoA reductase inhibitor to prevent graft vessel disease.
Statistical analysis
All data were expressed as mean ± standard deviation or medi-
an value. Long-term survival was derived by the Kaplan-Meier 
method with significance determined by log-rank analysis. All 
statistics were calculated using SPSS 17.0 software (SPSS Inc., 
Chicago, IL, USA). The level of significance was set at P < 0.05.
Ethics statement
This study was approved by Asan Medical Center ethics com-
mittee/institutional review board (study approval number 2010-
0310). Individual consent for the study was waived due to its 
retrospective medical record review design. 
RESULTS
The mean and median follow up period were 56.9 ± 44.6 and 
44.8 months (5.2 to 144.8 months). The mean ischemic time was 
149 ± 61.4 min. There were no early deaths, but seven late deaths 
occurred (7/37, 18.9%), three from rejection after 11, 15, and 41 
months; one from fungal pneumonia after 5 months; one caused 
by sepsis after 8 months; one from a fungal cerebral embolism 
after 10 months; and one from suspicious ventricular arrhyth-
mia after 50 months who had a syncope at the school, without 
documented arrhythmia at another hospital. The patient sud-
denly died while she was being transferred to our center (Table 
3). The actuarial 1-, 5-, and 10-yr survival rates were 88.6%, 76.8%, 
and 76.8%, respectively (Fig. 3). In one case, neurologic compli-
cation was occurred. This 12-yr-old patient (patient No. 5, Table 
2) had a permanent pacemaker after the Fontan operation. He 
suddenly suffered a sudden cardiac arrest due to ventricular fi-
brillation and received cardiopulmonary cerebral resuscitation. 
He underwent heart transplantation without pre-transplant neu-
rologic assessments. After the transplantation, we found that he 
had a hypoxic brain damage. He is now bed-ridden state.
  During the waiting period for heart transplantation, 16 pa-
tients (16/37, 43.3%) were hospitalized with inotropic support 
and 5 patients (5/37, 13.5%) were treated with ventilator support. 
There were 3 cases supported by extracorporeal membrane ox-
ygenation (ECMO); of them 2 cases as a bridge to transplanta-
tion and 1 case as postoperative support.
  The first 3-month-old patient with left ventricular outflow tract 
obstruction, mitral regurgitation, left ventricular (LV) dysfunc-
tion underwent corrective repair, but the baby was treated with 
EMCO due to low cardiac output and had been on 30 days of 
ECMO, he underwent transplantation and ECMO was weaned 
successfully in postoperative 7 days. And the second 13-yr-old 
Table 3. Causes of late mortality
Patient
Age at 
transplant 
(yr)
Diagnosis
Postoperative 
interval 
(months)
Cause of death
1 12.8  DCMP 5  Fungal pneumonia 
(Aspergillosis)
2 0.3  LVOTO, MR 8  Sepsis
3 15.8  DCMP 11  Rejection
4 8.6  DCMP 50  Suspicious ventricular 
arrhythmia
5 10  DORV with  
remote VSD, PA
41  Rejection
6 12.4  DCMP 10  Fungal cerebral 
embolism
Brain death
7 8.2  DCMP 15  Rejection
DCMP, dilated cardiomyopathy; LVOTO, left ventricular outflow tract obstruction; MR, 
mitral regurgitation; DORV, double outlet right ventricle; VSD, ventricular septal defect; 
PA, pulmonary atresia. Fig. 3. Kaplan–Meier cumulative survival of patients.
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patient with intramural coronary repair had a late LV dysfunc-
tion and was treated with ECMO for 14 days. He underwent heart 
transplantation and ECMO was weaned successfully in the op-
erating room. One patient with dilated cardiomyopathy (DCMP) 
was treated with ECMO immediate post-transplantation due to 
high pulmonary artery pressure (PAP), but the weaning was suc-
cessfully performed in postoperative 1 day. 
  We analyzed survival with risk factors including younger age 
less than 1 yr or 5 yr old, preoperative ventilatory support, pre-
operative inotropic support, creatinine level, bilirubin level, pre-
operative ECMO support, ischemic time, congenital heart dis-
ease, previous cardiac surgery, donor sex and recipient sex. There 
was no significant risk factor for survival.
  There were 25 rejections (25/37, 67.6%). Of these rejections 
less than grade II occurred in 17 patients (17/25, 68%) and re-
jections more than grade II occurred in 8 patients (8/25, 32%) 
(4). The patients with rejections more than grade II were treated 
methylprednisolone pulse therapy. Postoperatively, there were 
23 hypertension (23/37, 62.2%), 4 renal dysfunction (4/37, 10.8%), 
4 hyperlipidemia (4/37, 10.8%), 1 diabetes mellitus (1/37, 2.7%), 
2 coronary vasculopathy (2/37, 5.4%).
DISCUSSION
Heart transplantation has been recently accepted as a standard 
treatment for infants and children with end-stage cardiomyop-
athy or complex congenital heart disease. The overall post-trans-
plantation survival rate of these patients, from birth to 18 yr of 
age, is excellent (> 65% at 5 yr), comparable with the overall sur-
vival rate of adult transplant recipients. The overall 5- and 9-yr 
post-transplantation survival rates of pediatric heart recipients 
are approximately 65% and 60%, respectively (5). In this study, 
the actuarial 5- and 10-yr survival was 76.8%, which is higher 
than previously reported (1, 5, 6).
  In the past 15 yr, almost 400 pediatric heart transplantations 
per year have been performed worldwide, and about 100 per 
year involve infant recipients (1). Pediatric transplant recipients 
differ from adults with respect to indications, evaluation, surgi-
cal technique, and post-transplantation management (5). 
  The major difference between adult and pediatric recipients 
lies in the indications for transplantation. In adults, the main 
indications are equally divided between cardiomyopathies and 
coronary artery disease, with a minority of patients presenting 
with congenital heart disease. In comparison, the main indica-
tion for transplantation in children younger than 1 yr of age is 
congenital heart disease (> 75%), primarily involving hypoplas-
tic left heart syndrome (7). In the 1- to 10-yr age group, more 
than 50% of patients have cardiomyopathy and approximately 
37% have CHD; in adolescents, 11 to 17 yr of age, the main indi-
cation is cardiomyopathy in 64% and CHD in 26% (6). In this 
study, we had 1 case of CHD (1/1, 100%) younger than 1 yr, 3 
cases of CHD (3/11, 27.3%) in the 1- to 10-yr age group and 4 
cases of CHD in adolescents (4/25, 16%). Our data showed that 
number of recipient with CHD were decreasing as patients age 
getting older like other studies. Also, we had only 1 infant and 
no hypoplastic left heart syndrome case for which transplanta-
tion could be needed mostly. This might be due to the age limi-
tation more than 2 month old to be a donor by the National As-
sembly of the Republic of Korea (8).
  For successful treatment, or at least to improve the probabili-
ty of success and to reduce the risks of morbidity and mortality 
of transplantation, timely referral is essential. Although this ap-
plies to all pediatric patients, regardless of diagnosis, this is es-
pecially applicable to patients with CHD and end-stage cardiac 
failure because options for support are limited (5).
  Griffiths and colleagues (9) studied 34 Fontan patients who 
were treated with heart transplantation. They divided failing 
Fontan patients as two groups: impaired ventricular function 
(IVF) and those with preserved ventricular function (PVF) but 
with failing Fontan physiology (protein-losing enteropathy and 
plastic bronchitis). They found PVF group with failing Fontan 
physiology had a lower survival rates than IVF group after trans-
plantation and suggested necessity to improve the management 
and timing for transplantation amongst this group. Our series 
also included four patients with functional single ventricle, in-
cluding one with a bidirectional cavopulmonary shunt (BCS) 
and three with failing Fontan. All of these patients had impaired 
ventricular function before transplantation and 1 patient died 
of rejection after 41 months. Based on the study of Griffiths et 
al., we should pay special attention to the failing Fontan physi-
ology group with preserved ventricular function, not to miss the 
adequate timing for transplantation.
  Children with CHD referred for transplantation have often 
undergone several palliative surgical procedures, which increase 
post-transplantation surgical risks (5). Moreover, because of the 
limited number of donors, size-mismatched pediatric cardiac 
transplantation is common. Heart transplantation of oversized 
grafts is more difficult because of insufficient exposure, and lack 
of space of launching of donor heart. However, Razzouk et al. (10) 
reported that post-transplant morbidity and survival are not 
adversely influenced by the oversized heart. They also reported 
that whenever compression of the graft is a concern, the ster-
num is left open for a few days. We also had 2 cases of opened 
sternum, 1 patient with donor-recipient weight ratio 4.2, the 
other with 4.4. The last patient underwent delayed sternal clo-
sure after 5 months as already reported (11).
  Another concern with the use of large heart grafts has been 
the ‘big-heart or hyperperfusion syndrome’ (12). A strong, large 
donor heart may generate a high systemic pressure and exces-
sive cardiac output in the recipient who has previously endured 
a low-flow state. Such an acute rise in cerebral blood flow can 
cause reactive vasoconstriction and precipitate convulsions or Shin HJ, et al.  •  Heart Transplantation in Pediatric Patients: AMC Experience 
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coma. The danger of this syndrome is generally limited to the 
first few post-operative days. Soon after transplantation, the graft 
stroke volume is adjusted according to the recipient’s needs, 
and not to the donor’s requirements (13). We had 3 cases with 
donor-recipient weight ratio over than 2.5, but no cases showed 
big-heart syndrome.
  Management for growing children after transplantation is 
clearly different from adults. Most adult transplant recipients 
tolerate fairly uniform medication regimens and monitoring, 
but children’s drug metabolism varies significantly with age. 
Successful management for children lies not only in proper med-
ical treatment but also in considering for their growth and de-
velopment, especially adolescence period mood change (5).
  At present, we do not have psychological support programs 
which help the children and their families comply with long-
term medications after transplantation. We are planning to make 
a team, including consulting psychologists, social workers, sur-
geons, cardiologists, and transplant nurse coordinators who 
frequently contact with the patients and families. 
  According to tenth official pediatric heart transplantation re-
port - 2007 (1), CHD with younger than 1 yr, preoperative ECMO 
support, retransplant, preoperative ventilatory support or hos-
pitalization, donor age, creatinine, weight ratio, pediatric center 
transplant volume and bilirubin, female recipient and female 
donor were risk factors for mortality.
  In this study, we had 8 cases with CHD, 2 of them needed 
preoperative ECMO support. One 3 months old baby with com-
plex CHD needed preoperative ECMO support for 30 days died 
6 months later. The other 13-yr-old patient with congenital in-
tramural coronary artery needed preoperative ECMO support 
has been still alive. Both CHD and preoperative ECMO was not 
statistically significant risk factor. Preoperative ventilatory sup-
port was applied in 5 patients with one mortality. Preoperative 
in hospital care was needed in 16 cases with 3 mortalities. Also, 
these two factor were not significant risk factor. Overall, we could 
not find any significant risk factor in mortality. This result might 
be partly due to the small number of our patients especially those 
of neonates and infants. 
  In summary, our midterm results of pediatric heart transplan-
tation are excellent. We hope this result could be an encourag-
ing message to do more pediatric heart transplantation in Ko-
rean society.
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